Search Results - "Fedorak, Richard N"

An overview of clinical decision support systems: benefits, risks, and strategies for success by Sutton, Reed T., Pincock, David, Baumgart, Daniel C., Sadowski, Daniel C., Fedorak, Richard N., Kroeker, Karen I.

“…Computerized clinical decision support systems, or CDSS, represent a paradigm shift in healthcare today. CDSS are used to augment clinicians in their complex…”
Get full text

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease by Sandborn, William J, Feagan, Brian G, Rutgeerts, Paul, Hanauer, Stephen, Colombel, Jean-Frédéric, Sands, Bruce E, Lukas, Milan, Fedorak, Richard N, Lee, Scott, Bressler, Brian, Fox, Irving, Rosario, Maria, Sankoh, Serap, Xu, Jing, Stephens, Kristin, Milch, Catherine, Parikh, Asit

“…In this 52-week randomized trial, the α 4 β 7 integrin antibody vedolizumab was effective in treating Crohn's disease. The incidence of serious adverse events…”
Get full text

Larazotide Acetate for Persistent Symptoms of Celiac Disease Despite a Gluten-Free Diet: A Randomized Controlled Trial by Leffler, Daniel A, Kelly, Ciaran P, Green, Peter H.R, Fedorak, Richard N, DiMarino, Anthony, Perrow, Wendy, Rasmussen, Henrik, Wang, Chao, Bercik, Premysl, Bachir, Natalie M, Murray, Joseph A

“…Background & Aims Celiac disease (CeD) is a prevalent autoimmune condition. Recurrent signs and symptoms are common despite treatment with a gluten-free diet…”
Get full text

Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease by Bernard, Edmond-Jean, Fedorak, Richard N., Jairath, Vipul

“…Background and Aims Biosimilar approval, such as Inflectra™ (CT-P13) for treating ulcerative colitis (UC) and Crohn’s disease (CD), has reduced direct drug…”
Get full text

Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation by Paré, Pierre, Fedorak, Richard N

“…Constipation is an uncomfortable and common condition that affects many, irrespective of age. Since 1500 BC and before, health care practitioners have provided…”
Get full text

Incidence Rates for Surgery in Crohn’s Disease Have Decreased: A Population-based Time-trend Analysis by Dittrich, Alexandra E, Sutton, Reed Taylor, Haynes, Kate, Wang, Haili, Fedorak, Richard N, Kroeker, Karen I

“…Abstract Background Many Crohn’s disease (CD) patients will undergo surgery over the course of their life. It is thought that with the introduction of…”
Get full text

Vitamin D improves inflammatory bowel disease outcomes:Basic science and clinical review by Reich, Krista M, Fedorak, Richard N, Madsen, Karen, Kroeker, Karen I

“…Vitamin D deficiency is commonly diagnosed among patients with inflammatory bowel disease(IBD).Patients with IBD are at risk of low bone density and increased…”
Get full text

The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease by Fedorak, Richard N, Feagan, Brian G, Hotte, Naomi, Leddin, Des, Dieleman, Levinus A, Petrunia, Denis M, Enns, Robert, Bitton, Alain, Chiba, Naoki, Paré, Pierre, Rostom, Alaa, Marshall, John, Depew, William, Bernstein, Charles N, Panaccione, Remo, Aumais, Guy, Steinhart, A. Hillary, Cockeram, Alan, Bailey, Robert J, Gionchetti, Paolo, Wong, Cindy, Madsen, Karen

“…Background & Aims Probiotic formulations of single species of bacteria have not been effective in preventing the recurrence of Crohn’s disease after surgery…”
Get full text

Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial by Hanauer, Stephen B., Sandborn, William J., Rutgeerts, Paul, Fedorak, Richard N., Lukas, Milan, MacIntosh, Donald, Panaccione, Remo, Wolf, Douglas, Pollack, Paul

“…Background & Aims: Tumor necrosis factor blockade has been shown to be an effective treatment strategy in Crohn’s disease (CD). Adalimumab is a human…”
Get full text

Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease by Bressler, Brian, Panaccione, Remo, Fedorak, Richard N, Seidman, Ernest G

“…Objective monitoring of the severity of inflammation in patients with inflammatory bowel disease (IBD) is an essential part of disease management. However,…”
Get full text

Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial by Targan, Stephan R, Feagan, Brian G, Fedorak, Richard N, Lashner, Bret A, Panaccione, Remo, Present, Daniel H, Spehlmann, Martina E, Rutgeerts, Paul J, Tulassay, Zsolt, Volfova, Miroslava, Wolf, Douglas C, Hernandez, Chito, Bornstein, Jeffrey, Sandborn, William J

“…Background & Aims: A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn’s disease. Methods:…”
Get full text

Environment and the inflammatory bowel diseases by Frolkis, Alexandra, Dieleman, Levinus A, Barkema, Herman W, Panaccione, Remo, Ghosh, Subrata, Fedorak, Richard N, Madsen, Karen, Kaplan, Gilaad G

“…Inflammatory bowel diseases (IBD), which consists of Crohn disease and ulcerative colitis, are chronic inflammatory conditions of the gastrointestinal tract…”
Get full text

Distance management of inflammatory bowel disease:Systematic review and meta-analysis by Huang, Vivian W, Reich, Krista M, Fedorak, Richard N

“…AIM:To review the effectiveness of distance management methods in the management of adult inflammatory bowel disease(IBD)patients.METHODS:A systematic review…”
Get full text

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis by Thorlund, Kristian, Druyts, Eric, Mills, Edward J., Fedorak, Richard N., Marshall, John K.

“…A correction notice has been published, see: https://doi.org/10.1093/ecco-jcc/jjac104 To compare the efficacy of adalimumab and infliximab for the treatment of…”
Get full text

Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study by Keshteli, Ammar Hassanzadeh, van den Brand, Floris F, Madsen, Karen L, Mandal, Rupasri, Valcheva, Rosica, Kroeker, Karen I, Han, Beomsoo, Bell, Rhonda C, Cole, Janis, Hoevers, Thomas, Wishart, David S, Fedorak, Richard N, Dieleman, Levinus A

“…AIM To identify demographic, clinical, metabolomic, and lifestyle related predictors of relapse in adult ulcerative colitis(UC) patients.METHODS In this…”
Get full text

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease by Schreiber, Stefan, Rutgeerts, Paul, Fedorak, Richard N., Khaliq–Kareemi, Munaa, Kamm, Michael A., Boivin, Michel, Bernstein, Charles N., Staun, Michael, Thomsen, Ole Østergaard, Innes, Alison

“…Background & Aims: To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab′ fragment of anti–tumor necrosis factor, CDP870)…”
Get full text

Development and validation of an administrative case definition for inflammatory bowel diseases by Rezaie, Ali, Quan, Hude, Fedorak, Richard N, Panaccione, Remo, Hilsden, Robert J

“…A population-based database of inflammatory bowel disease (IBD) patients is invaluable to explore and monitor the epidemiology and outcome of the disease. In…”
Get full text

Infliximab Maintenance Therapy for Fistulizing Crohn's Disease by Sands, Bruce E, Anderson, Frank H, Bernstein, Charles N, Chey, William Y, Feagan, Brian G, Fedorak, Richard N, Kamm, Michael A, Korzenik, Joshua R, Lashner, Bret A, Onken, Jane E, Rachmilewitz, Daniel, Rutgeerts, Paul, Wild, Gary, Wolf, Douglas C, Marsters, Paul A, Travers, Suzanne B, Blank, Marion A, van Deventer, Sander J

“…Infliximab, a monoclonal antibody against tumor necrosis factor, reduces disease activity in patients with Crohn's disease. In this study of patients with…”
Get full text

Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease by Cheung, Justin, MD, FRCPC, Yu, Andrea, LaBossiere, Joseph, BSc, Zhu, Qiaohao, MSc, Fedorak, Richard N., MD, FRCPC

“…Background Patients with end-stage renal disease (ESRD) and peptic ulcer disease (PUD) bleeding may be at high risk of bleeding complications. Objective To…”
Get full text

Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response by Ma, Christopher, Huang, Vivian, Fedorak, Darryl K, Kroeker, Karen I, Dieleman, Levinus A, Halloran, Brendan P, Fedorak, Richard N

“…GOALS:To compare the proportion of secondary loss of response to adalimumab and infliximab during maintenance treatment of ulcerative colitis (UC) after…”
Get full text